Chris De Savi - Concepedia

Author

Chris De Savi

AstraZeneca (United Kingdom)

Also Known As

C De Savi, C SAVI, C Savi, C de Savi, C. DE SAVI, C. De Savi, C. Savi, C. de Savi, Chris De Savi, Chris De savi

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (United States)Blueprint Medicines (United States)Yonsei University

About

Chris De Savi is an author at AstraZeneca (United Kingdom) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	795
2	Natural Sciences	11	12	688
3	Biochemistry	9	10	661
4	Engineering	4	5	84
5	Allergy	1	1	32

Chris De Savi

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Discovery, Synthesis, and <i>in Vivo</i> Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase Andrew Mortlock, Kevin M. Foote, Nicola M. Heron, Journal of Medicinal Chemistry Pharmaceutical ScienceSelective InhibitorsPharmacotherapyAurora BChemical Biology	2007	270
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i> -Mutant Breast Tumors in Preclinical Models Hazel M. Weir, Robert H. Bradbury, Mandy Lawson, Cancer Research	2016	174
Optimization of a Novel Binding Motif to (<i>E</i>)-3-(3,5-Difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist Chris De Savi, Robert H. Bradbury, Alfred A. Rabow, Journal of Medicinal Chemistry Pharmaceutical SciencePharmacotherapyPositive Breast CancerPharmaceutical ChemistryMolecular Pharmacology	2015	159
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer Meredith S. Eno, Jason D. Brubaker, John E. Campbell, Journal of Medicinal Chemistry	2022	146
Total Synthesis of the Microtubule-Stabilizing Agent (−)-Laulimalide Ian Paterson, Chris De Savi, Matthew T. Tudge Organic Letters	2001	114
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies Bernard Barlaam, Robert Casella, Justin Cidado, Journal of Medicinal Chemistry	2020	98
Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors Frédéric Jung, Georges Pasquet, Christine Lambert‐van der Brempt, Journal of Medicinal Chemistry Planar ConformationPharmacotherapySelective Aurora AHeterocycle ChemistryChemical Biology	2006	92
1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC Stefanie S. Schalm, Tom Dineen, Sangbin Lim, Annals of Oncology Drug TargetingMedicineSelective 4ThGeneration Egfr TkiPharmacotherapy	2020	50
Investigation of (<i>E</i>)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators Sébastien L. Degorce, Andrew Bailey, Rowena Callis, Journal of Medicinal Chemistry Breast OncologyFemale Reproductive FunctionPharmacotherapyMolecular PharmacologyMedicinal Chemistry	2015	42
Efficacious Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD Chris De Savi, Rhona J. Cox, Daniel J. Warner, Journal of Medicinal Chemistry AsthmaPde4 InhibitorsMedicinal ChemistryTranslational MedicineOral Phosphodiesterase 4	2014	32

Page 1